BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 23 filers reported holding BAXTER INTL INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $186,813 | -17.2% | 4,950 | 0.0% | 0.01% | -10.0% |
| Q2 2023 | $225,522 | -3.6% | 4,950 | -14.2% | 0.01% | -9.1% |
| Q1 2023 | $234,031 | +79502.4% | 5,770 | 0.0% | 0.01% | -15.4% |
| Q4 2022 | $294 | -99.9% | 5,770 | -1.9% | 0.01% | -13.3% |
| Q3 2022 | $317,000 | -19.1% | 5,882 | -3.6% | 0.02% | -11.8% |
| Q2 2022 | $392,000 | -25.9% | 6,100 | -10.5% | 0.02% | -10.5% |
| Q1 2022 | $529,000 | -19.0% | 6,816 | -10.5% | 0.02% | -9.5% |
| Q4 2021 | $653,000 | +172.1% | 7,615 | +157.7% | 0.02% | +31.2% |
| Q1 2020 | $240,000 | +17.1% | 2,955 | +3.0% | 0.02% | -11.1% |
| Q3 2014 | $205,000 | -18.7% | 2,868 | -17.5% | 0.02% | -18.2% |
| Q2 2014 | $252,000 | -11.3% | 3,477 | -10.0% | 0.02% | -15.4% |
| Q1 2014 | $284,000 | -17.2% | 3,862 | -21.9% | 0.03% | -18.8% |
| Q4 2013 | $343,000 | -36.0% | 4,943 | -39.4% | 0.03% | -39.6% |
| Q3 2013 | $536,000 | -71.2% | 8,158 | -69.7% | 0.05% | -72.5% |
| Q2 2013 | $1,862,000 | – | 26,880 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |